Switch theme
Sign up to access all valuation multiples
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
2017
116
Last FY Revenue n/a
LTM EBITDA -$104M
-$55.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mural Oncology has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$104M.
In the most recent fiscal year, Mural Oncology achieved revenue of n/a and an EBITDA of -$135M.
Mural Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mural Oncology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$104M | XXX | -$135M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$125M | XXX | -$138M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$118M | XXX | -$129M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mural Oncology's stock price is $3.
Mural Oncology has current market cap of $45.2M, and EV of -$55.7M.
See Mural Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$55.7M | $45.2M | XXX | XXX | XXX | XXX | $-6.66 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mural Oncology has market cap of $45.2M and EV of -$55.7M.
Mural Oncology's trades at n/a EV/Revenue multiple, and 0.4x EV/EBITDA.
Equity research analysts estimate Mural Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mural Oncology has a P/E ratio of -0.4x.
See valuation multiples for Mural Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45.2M | XXX | $45.2M | XXX | XXX | XXX |
| EV (current) | -$55.7M | XXX | -$55.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.5x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBIT | 0.4x | XXX | 0.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMural Oncology's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
Mural Oncology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mural Oncology's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mural Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -65% | XXX | -45% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mural Oncology acquired XXX companies to date.
Last acquisition by Mural Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Mural Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mural Oncology founded? | Mural Oncology was founded in 2017. |
| Where is Mural Oncology headquartered? | Mural Oncology is headquartered in United States of America. |
| How many employees does Mural Oncology have? | As of today, Mural Oncology has 116 employees. |
| Who is the CEO of Mural Oncology? | Mural Oncology's CEO is Dr. Caroline Loew, PhD. |
| Is Mural Oncology publicy listed? | Yes, Mural Oncology is a public company listed on NAS. |
| What is the stock symbol of Mural Oncology? | Mural Oncology trades under MURA ticker. |
| When did Mural Oncology go public? | Mural Oncology went public in 2023. |
| Who are competitors of Mural Oncology? | Similar companies to Mural Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Mural Oncology? | Mural Oncology's current market cap is $45.2M |
| Is Mural Oncology profitable? | Yes, Mural Oncology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mural Oncology? | Mural Oncology's last 12 months EBITDA is -$104M. |
| What is the current EV/EBITDA multiple of Mural Oncology? | Current EBITDA multiple of Mural Oncology is 0.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
